/About
About2018-10-30T16:01:53+00:00

Realize the power of ctmDNA

  • Easily identify disease-specific ctmDNA - Broad genomic screening technology from disease-state tissues coupled with sophisticated machine learning quickly identifies targets of interest

  • Fast targeted ctmDNA assay development – Custom design of targeted ctmDNA assay quickly produces statistically powerful datasets

  • Easy lab implementation – Custom kits for both Illumina and Thermo Fisher Scientific NGS to run in your laboratory takes only 1 day from DNA to sequencer-ready library

ctmDNA is a novel analyte with many possibilities for cancer and other disease states. Contact us today for collaboration partnership opportunities.

Contact Us

The Co-Founders of Singlera Genomics

Yuan Gao, CEO and Co-Founder of Singlera Genomics
Dr. Yuan Gao Ph.D., Chairman and Co-Founder
Dr. Kun Zhang Co-Founder Singlera Genomics
Kun Zhang, Ph.D., Co-founder and Scientific Advisor
Johny Zhang MBA
Johny Zhang, M.B.A., Co-Founder, Chief Executive Officer
Dr. Rui Liu CTO Singlera Genomics
Rui Liu, Ph.D., Co-Founder, Chief Technology Officer
Qiang Liu MBA
Qiang Liu, M.B.A., Co-Founder, Chief Operating Officer

Scientific Advisory Board

Prof. Jin Li, Vice President of Fudan University; elected member of Chinese Academy of Science
Prof. George Church, Harvard Medical School, elected member of NAS, NAE, AAAS
Prof. Zhou Honghao, Dir of Inst of Pharmacology, Central South Univ.; elected member of Chinese Academy of Engineering
Prof. Liu Xiaole, Dept of Biostatistics, Harvard University; Thousand Talents Program, Prof of Tongji University
Prof. Cheng Liang, Professor of pathology at the Indiana University Medical School
Dr. Kun Zhang Co-Founder Singlera Genomics
Prof. Kun Zhang, Department of Bioengineering, University of California at San Diego
Prof. Yuan (Gary) Gao, Department of Biomedical Engineering, Johns Hopkins University

China Team

Singlera Genomics has a team in Shanghai China dedicated to serving the Chinese market.

The Shanghai facility manufactures, markets, sells and supports applications for both non-invasive prenatal testing (NIPT) as well as oncology.

Discover The Future

At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future.

Contact Us
Email Signup
Good things come to those who sign up for
An Early Mark
Join our email list to get the latest blog posts straight to your inbox
SUBSCRIBE
Give it a try, you can unsubscribe anytime.
close-link